Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
June 01, 2018 08:00 ET
|
NOVARTIS FINANCE S.A.
Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)...
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
June 01, 2018 07:40 ET
|
NOVARTIS FINANCE S.A.
If approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package...
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
May 17, 2018 19:13 ET
|
NOVARTIS FINANCE S.A.
Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin...
Novartis announces changes to the Executive Committee
May 16, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services ...
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
May 02, 2018 22:06 ET
|
NOVARTIS FINANCE S.A.
Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing...
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
May 01, 2018 16:26 ET
|
NOVARTIS FINANCE S.A.
Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only...
Novartis provides update on proposed acquisition of AveXis
May 01, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Basel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable...
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
April 19, 2018 01:15 ET
|
NOVARTIS FINANCE S.A.
Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1,...
Novartis delivered a strong first quarter and acted to become a more focused medicines company
April 19, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong...
Novartis tender offer for AveXis commences
April 17, 2018 01:00 ET
|
NOVARTIS FINANCE S.A.
Basel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has...